Immunocytochemical evaluation of proliferative activity in human brain tumours

M. Girino, A. Riccardi, M. Danova, P. Gaetani, G. Butti, M. Giordano, A. Cuomo

Research output: Contribution to journalArticlepeer-review


The immunocytochemical expression of the antigen reacting with the monoclonal antibody Ki-67 (Ki-67 positivity) was investigated in 50 imprint preparations from human brain tumours. Data were related to tumour proliferative activity, as determined from in vivo bromodeoxyuridine (BrdU) incorporation (BrdU-labelling index, BrdU-LI) and histology. The percentage of Ki-67-positive cells was greater than the corresponding BrdU-LI value in all tumours, and the differences in Ki-67 positivity among tumour subtypes paralleled the BrdU-LI differences. Both the BrdU-LI and the percentage of Ki-67 positive cells were significantly greater (P <0.005) in the group of clinically aggressive adult tumours, histologically identified as anaplastic astrocytomas and glioblastomas, than in the less aggressive ones (oligodendroglioma, meningiomas, schwannomas, pituitary adenomas, dermoid cyst) and in the cerebral metastatic localizations. These data suggest that Ki-67 positivity, which is easily evaluated with immunocytochemistry, is related to the proliferative activity of brain tumours and that this parameter is endowed with clinical significance.

Original languageEnglish
Pages (from-to)269-275
Number of pages7
JournalAnalytical Cellular Pathology
Issue number5
Publication statusPublished - Sep 1990


  • Bromodeoxyuridine
  • Human brain tumour
  • Monoclonal antibody Ki-67
  • Proliferative activity

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology


Dive into the research topics of 'Immunocytochemical evaluation of proliferative activity in human brain tumours'. Together they form a unique fingerprint.

Cite this